[Irreversible, non-selective monoamine oxidase inhibitors].
Irreversible, non-selective monoamine oxidase (MAO) inhibitors were among the first antidepressants. No drugs in this group are currently marketed in Norway, but many physicians will see patients using them, as they can be prescribed on a named patient basis after application to the Norwegian Medicines Agency. This article presents adverse effects, interactions and precautions related to the use of these drugs.
Castberg
Ingrid
I
Psykisk helsevern avdeling Østmarka, St. Olavs hospital, Postboks 3008 Lade, 7441 Trondheim. ingrid.castberg@stolav.no
Spigset
Olav
O
D000928:Antidepressive Agents / Q000009:adverse effects*; D001628:Beverages; D004347:Drug Interactions; D018565:Food-Drug Interactions; D006801:Humans; D007520:Isocarboxazid / Q000009:adverse effects; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects*; D010353:Patient Education as Topic; D010624:Phenelzine / Q000009:adverse effects; D012307:Risk Factors; D020230:Serotonin Syndrome / Q000139:chemically induced; D014191:Tranylcypromine / Q000009:adverse effects
D000928:Antidepressive Agents; D008996:Monoamine Oxidase Inhibitors; D007520:Isocarboxazid; D014191:Tranylcypromine; D010624:Phenelzine